Hopp til hovedinnhold

Kul i skjoldkjertelen

En kul i skjoldkjertelen gir oftest ingen symptomer, og kulen blir ofte funnet av en lege i forbindelse med en rutineundersøkelse.

Sist revidert:

QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/hormoner-og-naring/skjoldkjertelsykdommer/skjoldkjertelen-kul/ 

Hva er en kul i skjoldkjertelen?

Symptomer

Diagnosen

Behandling

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Thyroideakreft. Referanselisten for dette dokumentet vises nedenfor.

  1. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for utredning, behandling og oppfølgning av kreft i skjoldbruskkjertelen. Nasjonale faglige retningslinjer, 06/2017. helsedirektoratet.no 
  2. Tangerud Å, Sigstad E, Fagerlid KH, Paulsen TH, Norheim I. Knuter i tyreoidea - utredning og oppfølging. Tidsskr Nor Legeforen 2020. doi:10.4045/tidsskr.20.0186 DOI 
  3. Kreftregisteret. Cancer in Norway 2020. Oslo: Kreftregisteret, 2021. www.kreftregisteret.no. www.kreftregisteret.no 
  4. Deng Y, Li HT, Wang M, et al. Global Burden of Thyroid Cancer From 1990 to 2017. JAMA Netw Open 2020; 3: e208759. doi:10.1001/jamanetworkopen.2020.8759 DOI 
  5. Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212. PubMed 
  6. Lim H, Devesa SS, Sosa JA, et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA 2017; 317: 1338-48. pmid:28362912 PubMed 
  7. Haugen BR, Alexander EK, Bible KC et al. 2015 American Thyroid Association Management Guidelines for Adult Patients With Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26: 1-133. pmid:26462967 PubMed 
  8. Datta R. Thyroid cancer. BMJ Best Practice, last reviewed December 2018. bestpractice.bmj.com 
  9. McCartney CR, Stukenborg GJ. Decision analysis of discordant thyroid nodule biopsy guideline criteria. J Clin Endocrinol Metab 2008; 93: 3037-44. PubMed 
  10. Leboulleux S, Bournaud C, Chougnet CN, et al. Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer. N Engl J Med 2022; 386: 923.932. pmid:35263518 PubMed 
  11. Wells SA Jr, Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134. pmid:22025146 PubMed 
  12. Elisei R1, Schlumberger MJ, Müller SP et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2014; 32: 1864. pmid:24002501 PubMed 
  13. Tuttle RM, Ross DS, Mulder JE. Differentiated thyroid cancer: Overview of management. UpToDate. Last updated May 12, 2016. www.uptodate.com 
  14. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30 . PMID: 25671254 PubMed 
  15. Brose MS, Nutting CM, Jarzab B et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014; 384: 319-28. pmid:24768112 PubMed 
  16. Viola D, Valerio L, Molinaro E et al. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer 2016; 23: 185-205. pmid:27207700 PubMed 
  17. Lin JS, Bowles EJA, Williams SB et al. Screening for Thyroid Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2017; 317: 1888-903. pmid:28492904 PubMed 
  18. McLeod, DS, Sawka, AM, Cooper, DS. Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet 2013; 381: 1046-57. pmid:23668555 PubMed